Previous Section Index Home Page

11 Sep 2006 : Column 2245W—continued


11 Sep 2006 : Column 2246W

NICE

Justine Greening: To ask the Secretary of State for Health which drugs were not approved by the National Institute for Health and Clinical Excellence which were assessed to have a cost per quality-adjusted-life-year of between £30,000 and £35,000 in each year since 2000; and if she will make a statement. [87745]

Andy Burnham [holding answer 24 July 2006]: An analysis has been undertaken of drugs not approved by the National Institute for Health and Clinical Excellence (NICE), taking into account appraisals published between 1 January 2000 and 27 July 2006. Of the drugs appraised but not approved by NICE, none fell exactly into the cost quality-adjusted-life-year (QALY) range of between £30,000 and £35,000, although NICE’s appraisal of Anakinra for rheumatoid arthritis (published in November 2003) identified a wide potential cost per QALY range of between £20,000 and £952,000. Further information on this appraisal can be found on NICE’s website at www.nice.org.uk

Small Change Big Difference

Anne Milton: To ask the Secretary of State for Health pursuant to the answer of 31 May 2006, Official Report, column 31W, on Small Change Big Difference; how much the campaign has cost; and how much money has been allocated for the entirety of the campaign. [79761]

Caroline Flint: The Department has spent under £1,000 on the launch of the initiative. Small Change Big Difference is the working title for our social marketing strategy for England—a key Choosing Health commitment. The Department is currently developing the strategy over the next five years so the entire cost has yet to be determined.


    Index Home Page